Escape from the extremely stressful opiate withdrawal syndrome may motivate opiate seeking and taking. The corticotropin-releasing factor receptor-1 (CRF 1 ) pathway mediates behavioral and endocrine responses to stress. Here, we report that genetic inactivation (CRF 1 À/À ) as well as pharmacological antagonism of the CRF/ CRF 1 receptor pathway increased and prolonged the somatic expression of opiate withdrawal. Opiate-withdrawn CRF 1 À/À mice also showed aberrant CRF and dynorphin expression in the paraventricular nucleus of the hypothalamus (PVN) and the striatum, indicating profound impairments in stress-responsive brain circuitry. Intake of nonstressful amounts of corticosterone effectively reduced the exaggerated somatic reactions of CRF 1 À/À mice to opiate withdrawal. Exogenous corticosterone also restored ''wild-type-like'' patterns of CRF and dynorphin gene expression in the PVN and the striatum of opiate-withdrawn CRF 1 À/À mice, respectively. The present findings unravel a key role for the hypothalamus-pituitary-adrenal (HPA) system and brain extra-hypothalamic CRF/CRF 1 receptor circuitry in somatic, molecular, and endocrine alterations induced by opiate withdrawal.
INTRODUCTION
Opiate dependence is a major public health issue whose incidence rate may dramatically increase in the next years. Recent reports show an alarming raise in the recreational use of heroin and other opiate drugs among adolescents (NIDA, 2005) . In opiate-dependent individuals, heroin ''highs'' are inexorably followed by a severe opiate withdrawal syndrome comprised of somatic signs and symptoms and negative affective states (O'Brien, 1996) . Besides a positive reinforcement theory of drug addiction (Shaham et al., 2003) , studies indicate that escape from the extremely aversive and stressful opiate withdrawal syndrome may motivate heroin-seeking and -taking behaviors (Carrera et al., 1999; Kenny et al., 2006; Lu et al., 2005; Schulteis and Koob, 1996) . However, current treatments do not effectively relieve the opiate withdrawal syndrome, thus leaving opiate-dependent individuals vulnerable to relapse to drug intake.
The corticotropin-releasing factor (CRF) system is a major coordinator of behavioral and endocrine responses to stress (Heinrichs et al., 1994; Rivier and Vale, 1983) . The CRF system might also mediate the motivational effects of drug dependence. Functional antagonism of CRF neurotransmission reduces stress-induced reinstatement of drug-seeking behavior and ameliorates negative affective-like states associated with alcohol, cocaine, or opiate withdrawal (Heinrichs et al., 1995; Sarnyai et al., 1995; Shaham et al., 1998; Stinus et al., 2005; Valdez et al., 2002) . The studies cited above suggest new therapeutic strategies for opiate dependence.
In mammals, CRF actions are mediated by two distinct receptor pathways, termed CRF 1 and CRF 2 (Hauger et al., 2003) . Genetically engineered mouse models have allowed the observation of distinct, and often opposite, functions for the two known CRF receptor pathways in HPA axis and affective-like behavioral responses to stressors (Bale and Vale, 2004; Contarino and Gold, 2002) . In particular, studies with CRF 1 receptor-deficient mice have revealed that the CRF/CRF 1 receptor pathway mediates HPA axis functions and behavioral strategies essential to cope with stressful events (Contarino et al., 1999; Smith et al., 1998; Timpl et al., 1998) . Moreover, using CRF 1 receptor-deficient mice, we have recently found that disruption of the CRF/CRF 1 receptor pathway eliminates the negative affective states of opiate withdrawal (Contarino and Papaleo, 2005) . However, the involvement of the stress-responsive HPA system and brain extrahypothalamic CRF/CRF 1 receptor circuitry in behavioral, gene expression, and endocrine alterations relevant to somatic opiate withdrawal remains largely unknown.
To elucidate the role for the CRF/CRF 1 receptor pathway in somatic components of the opiate withdrawal syndrome, here we used CRF 1 receptor-deficient (CRF 1 +/À and CRF 1 À/À ) mice and the CRF 1 receptor-preferring antagonist antalarmin (Smith et al., 1998; Wong et al., 1999) . In keeping with the clinical setting, where signs and symptoms of opiate withdrawal ''spontaneously'' and gradually rise along with the drug removal from the body (O'Brien, 1996) , our studies were conducted in mice undergoing spontaneous opiate withdrawal. Active heroindependent individuals have reduced plasma levels of corticotropin (ACTH) and cortisol, flattened circadian rhythms of cortisol, and blunted HPA axis responses to stressors (Facchinetti et al., 1985; Kreek and Koob, 1998) ; however, the physiopathological role for these alterations in somatic components of the opiate withdrawal syndrome remains largely unknown. CRF 1 À/À mice also display flattened circadian rhythms of corticosterone, the main glucocorticoid hormone in rodents, and deficient ACTH and corticosterone responses to stressors (Smith et al., 1998; Timpl et al., 1998) . Thus, to examine the specific contribution of impaired HPA axis functions to opiate withdrawal, we treated CRF 1 À/À mice with nonstressful amounts of corticosterone. Moreover, the use of antalarmin allowed us to investigate the HPA axis-independent role for the CRF/ CRF 1 receptor pathway in opiate withdrawal. Antalarmin attenuates behavioral responses to stress but does not affect basal or stress-related activity of the HPA axis (Deak et al., 1999; Jutkiewicz et al., 2005; Wong et al., 1999; Zorrilla et al., 2002) . Furthermore, we examined the specific role for impaired HPA axis functions associated with the CRF 1 receptor deficiency upon opiate withdrawalinduced expression of CRF and the opioid peptide dynorphin in the PVN and the striatum, brain regions integrating behavioral, endocrine, and autonomic responses to stress (Koob and Heinrichs, 1999; Reyes et al., 2005) . PVN CRF drives basal and stress-related activity of the HPA axis (Sawchenko et al., 1993) ; also, hypothalamic dynorphin and CRF circuitry are activated during the stress of opiate withdrawal (Houshyar et al., 2004; Lightman and Young, 1988; Rattan et al., 1992) . Moreover, recent evidence indicates a role for striatal dynorphin circuitry in somatic components of the opiate withdrawal syndrome (Zachariou et al., 2006) . The present study reveals a fundamental role for the HPA system and brain extrahypothalamic CRF/CRF 1 receptor circuitry in somatic, gene expression, and endocrine changes associated with the stressful condition of opiate withdrawal. , and CRF 1 À/À mice were repeatedly treated with escalating morphine doses. Unlike constant morphine infusions or pellets, intermittent treatment with escalating morphine doses closely parallels the drug intake pattern of opiatedependent humans. Also, in rodents termination of intermittent morphine treatment is followed by HPA axis alterations that are similar to those seen in opiate-withdrawn humans (Houshyar et al., 2004) . CRF 1 receptor deficiency did not affect body weight (BW) loss induced by intermittent morphine administration (see Figure S1 in the Supplemental Data available with this article online). Analysis of somatic opiate withdrawal occurring 8 hr after the last morphine injection revealed a genotype 3 opiate withdrawal interaction effect for the jump (F 2,49 = 4.18, p < 0.05), wet dog shake (F 2,49 = 3.35, p < 0.05), and diarrhea (F 2,49 = 3.84, p < 0.05) signs. Opiate-withdrawn CRF 1 À/À mice made more jumps (p < 0.01; Figure 1A ), wet dog shakes (p < 0.005; Figure 1B ), and diarrhea (p < 0.01; Figure 1C ) than all other groups. In contrast, opiate-withdrawn wild-type and CRF 1 +/À mice did not differ from control mice (Figures 1A, 1B, and 1C) . Accordingly, during the conditioning trials of an opiate withdrawal conditioned place aversion experiment, opiate-withdrawn CRF 1 À/À mice displayed elevated levels of jumping and wet dog shake, as compared to wild-type and CRF 1 +/À mice (Contarino and Papaleo, 2005) . CRF 1 receptor deficiency did not affect other opiate withdrawal signs: overall, opiatewithdrawn mice showed more paw tremors (F 1,49 = 9.93, p < 0.005), body stretches (F 1,49 = 11.99, p < 0.005), chews (F 1,49 = 20.47, p < 0.0001), teeth chatters (F 1,49 = 9.46, p < 0.005), palpebral ptoses (F 1,49 = 4.17, p < 0.05), and body weight loss (F 1,49 = 21.10, p < 0.0001) than control mice ( Figure S2 ). Analysis of global opiate withdrawal (GOW) scores also revealed a genotype 3 opiate withdrawal interaction effect (F 2,49 = 8.00, p < 0.001). Opiate-withdrawn wild-type, CRF 1 +/À , and CRF 1 À/À mice displayed higher GOW scores than control mice (p < 0.005). In addition, opiate-withdrawn CRF 1 À/À mice showed higher GOW scores than opiate-withdrawn wild-type and CRF 1 +/À mice (p < 0.0005; Figure 1D ). These results clearly indicate a dramatic increase in major somatic signs of opiate withdrawal in mice lacking functional levels of CRF 1 receptors.
RESULTS

Increased
Another cohort of wild-type, CRF 1 +/À , and CRF 1 À/À mice was used to assess the duration of somatic opiate withdrawal. Monitoring of opiate withdrawal up to 152 hr after the last morphine injection revealed a genotype 3 opiate withdrawal 3 time interaction effect (F 10,155 = 2.12, p < 0.05). CRF 1 À/À mice displayed elevated GOW scores at least up to 104 hr after the last opiate injection (p < 0.05 versus all other groups). In net contrast, in wild-type and CRF 1 +/À mice somatic opiate withdrawal lasted less than 32 hr ( Figure 1E ). Thus, somatic opiate withdrawal was not only more severe but also lasted much longer in CRF 1 (Almeida et al., 1992) as well as stressinduced decreases in PVN CRF expression (Tanimura and Watts, 1998) . Furthermore, here we show that CRF 1 +/À mice, which display neither basal nor stress-related ACTH or corticosterone deficits (Contarino and Papaleo, 2005; Timpl et al., 1998) , displayed PVN CRF and dynorphin given free access to corticosterone in the home-cage drinking water throughout intermittent opiate administration. Corticosterone intake restored nadir plasma corticosterone levels (p < 0.05 versus corticosterone-untreated CRF 1 À/À mice) but did not produce ''stressful'' plasma corticosterone concentrations throughout the light-dark cycle of the housing room ( Figure 3 ). Eight hours after the last opiate injection, corticosterone-untreated opiatewithdrawn CRF 1 À/À mice showed higher levels of paw tremor (p < 0.0005; Figure 4A ), wet dog shake (p < 0.0005; Figure 4B ), diarrhea (p < 0.005; Figure 4C ), and GOW scores (p < 0.0005; Figure 4D ) than control mice and opiate-withdrawn wild-type mice. Treatment with corticosterone effectively reduced paw tremors, wet dog shakes, and GOW scores in CRF 1 À/À mice (p < 0.0005 versus corticosterone-untreated opiate-withdrawn CRF 1 À/À mice), completely abolishing the difference between opiatewithdrawn CRF 1 À/À and wild-type mice, but did not affect the diarrhea sign ( Figures 4A, 4B , 4C, and 4D). These results clearly indicate that deficient HPA axis activity strongly contributes to aggravate the somatic outcome of opiate withdrawal. At the end of the 30 min opiate withdrawal test, corticosterone-treated and -untreated CRF 1 À/À mice had similar plasma corticosterone levels that were much lower than the stress-like levels displayed by wild-type mice (p < 0.0005; Figure S3 ). The latter results indicate that the beneficial effects of exogenous corticosterone upon somatic components of opiate withdrawal were not accompanied by a stress-like activity of the HPA axis.
To examine if the decrease of somatic opiate withdrawal by intake of nonstressful amounts of corticosterone was associated to brain region-specific changes in gene expression, we examined CRF and dynorphin mRNA levels in the PVN and the striatum of control and opiate-withdrawn wild-type, corticosterone-untreated, or -treated CRF 1 À/À mice. Analysis of PVN CRF expression (bregma interval À0.94/À1.22 mm) revealed a group 3 opiate withdrawal interaction effect (F 2,103 = 31.17, p < 0.0001). As in our prior experiment reported above, opiate withdrawal increased CRF expression in wild-type mice (p < 0.0005 versus control wild-type mice); in net contrast, opiatewithdrawn corticosterone-untreated CRF 1 À/À mice displayed an aberrant decrease in CRF activity (p < 0.0005 versus corticosterone-untreated control CRF 1 À/À mice; Figure 5A ). Intake of corticosterone strongly reduced PVN CRF expression in control CRF 1 À/À mice (p < 0.0005 versus control corticosterone-untreated CRF 1 À/À mice; Figure 5A ). Most interestingly, similar to the wild-type mice, opiate-withdrawn corticosterone-treated CRF 1 Values represent mean ± SEM. n = 7-11 mice/group. *p < 0.005 versus control and opiate-withdrawn wild-type and CRF 1 +/À mice, **p < Figure 6A ). Opiate withdrawal increased PVN dynorphin expression in either corticosterone-untreated or -treated CRF 1 À/À mice (p < 0.0005 versus control CRF 1 À/À mice; Figure 6A) ; however, the latter displayed lower dynorphin mRNA levels than the former group (p < 0.05; Figure 6A ). Previous studies have shown increased dynorphin gene expression in the PVN of opiate-withdrawn rats (Lightman and Young, 1988) . Thus, we examined PVN dynorphin mRNA levels in another coronal slice (bregma interval À0.70/À0.82 mm). The latter analysis revealed a group 3 opiate withdrawal interaction effect (F 2,56 = 3.61, p < 0.05). At this coronal level, both wild-type and corticosterone-untreated CRF 1 À/À mice showed increased PVN dynorphin expression in response to opiate withdrawal (p < 0.05 versus same genotype control mice; Figure 6B ). In net contrast, in CRF 1 À/À mice corticosterone completely abolished the opiate withdrawal-induced dynorphin mRNA increase (p < 0.01 versus opiate-withdrawn corticosteroneuntreated CRF 1 À/À mice; Figure 6B ).
Thus, corticosterone intake decreased both basal and opiate withdrawal-related PVN dynorphin expression in CRF 1 À/À mice. Noteworthy, at both brain coronal sections examined here, opiate-withdrawn corticosterone-treated Examination of dynorphin expression in the striatum also revealed a group 3 opiate withdrawal interaction effect (F 2,87 = 10.15, p < 0.0005). Overall, either corticosterone-untreated or -treated CRF 1 À/À mice showed lower dynorphin expression than wild-type mice (p < 0.0005; Figure 7 ). In wild-type mice, opiate withdrawal decreased the striatal expression of dynorphin (p < 0.0005 versus control wild-type mice; Figure 7 ). The latter results agree with previous studies showing decreased dynorphin expression in rats withdrawn from chronic exposure to morphine (Georges et al., 1999; Tjon et al., 1997) . In net contrast, although not significantly, opiate withdrawal increased striatal dynorphin mRNA levels in corticosterone-untreated CRF 1 À/À mice (p = 0.070 versus control corticosterone-untreated CRF 1 À/À mice). Corticosterone intake raised striatal dynorphin expression in control CRF 1 À/À mice (p < 0.01 versus control corticosteroneuntreated CRF 1 À/À mice; Figure 7 ). Most importantly, contrary to the corticosterone-untreated CRF 1 À/À mice, opiate withdrawal decreased striatal dynorphin expression in corticosterone-treated CRF 1 À/À mice (p < 0.05 versus control corticosterone-treated CRF 1 À/À mice; Figure 7 ).
Thus, similar to the wild-type mice, corticosterone-treated opiate-withdrawn CRF 1 À/À mice displayed decreased, instead of increased, dynorphin gene expression in the striatum.
Pharmacological Disruption of the CRF/CRF 1 Receptor Pathway Exacerbates the Somatic Signs of Opiate Withdrawal
To assess the HPA axis-independent role for the CRF/ CRF 1 receptor pathway in somatic opiate withdrawal, we used the CRF 1 receptor-preferring antagonist antalarmin. Following peripheral administration, antalarmin readily crosses the blood-brain barrier and does not affect basal or stress-related activity of the HPA axis (Jutkiewicz et al., 2005; Wong et al., 1999) . Antalarmin-treated opiatewithdrawn wild-type and CRF 1 +/À mice showed higher levels of paw tremor (F 1,30 = 17.84, p < 0.0005; Figure 8A ), chew (F 1,30 = 29.21, p < 0.0001; Figure 8B ), body stretch (F 1,30 = 5.35, p < 0.05; Figure 8C ), and GOW scores (F 1,30 = 22.36, p < 0.0001; Figure 8D ) than vehicle-treated opiate-withdrawn mice. Antalarmin did not affect the expression of other opiate withdrawal signs (data not shown). At the end of the 30 min opiate withdrawal test, antalarmin-and vehicle-treated wild-type mice displayed similar plasma corticosterone levels ( Figure S4 ), indicating that the CRF 1 receptor antagonist did not affect HPA axis responses to the stress of opiate withdrawal. These results clearly indicate that pharmacological disruption of the brain extrahypothalamic CRF/CRF 1 receptor pathway exacerbates the somatic expression of opiate withdrawal.
DISCUSSION
This report demonstrates, by both a genetic and a pharmacological approach, that disruption of the CRF/CRF 1 receptor pathway and related HPA axis activity dramatically increases the somatic expression of opiate withdrawal. In particular, CRF 1 À/À mice showed increased levels of somatic opiate withdrawal as well as aberrant CRF and dynorphin gene expression in the PVN and striatum brain regions. Intake of nonstressful amounts of corticosterone prior to and throughout morphine exposure reliably reduced the exacerbated somatic reactions of CRF 1 À/À mice to opiate withdrawal. Also, corticosterone intake restored ''wild-type-like'' patterns of opiate withdrawalinduced PVN CRF and striatal dynorphin gene expression in CRF 1 À/À mice. The use of antalarmin also allowed us to unravel a HPA axis-independent modulatory (inhibitory) role for brain CRF/CRF 1 receptor circuitry upon the somatic expression of opiate withdrawal.
To mimic the clinical setting, in the present study mice were treated with intermittent escalating morphine doses and opiate withdrawal-related alterations assessed following ''spontaneous'' drug clearance from the body. Using such a clinically oriented paradigm, we found that during early opiate withdrawal, i.e., 8 hr after the last morphine injection, CRF 1 À/À mice displayed elevated levels of somatic malaise, as compared to wild-type and CRF 1 +/À mice. Somatic opiate withdrawal signs were not only more severe but also lasted much longer in CRF 1 À/À mice than in wild-type and CRF 1 +/À mice. In CRF 1 À/À mice, reliable signs of opiate withdrawal could be detected at least up to 104 hr after the last opiate injection; in net contrast, in wild-type and CRF 1 +/À mice somatic opiate withdrawal lasted less than 32 hr. In the present study, like in the clinical setting, between successive morphine injections the mice experienced the malaise of opiate withdrawal. The twice-daily partial opiate withdrawal that accompanied our drug regimen may have served as a severe chronic stressor. Accordingly, 12 hr after morphine dosing, rats treated with a morphine regimen similar to that used here displayed stress-like alterations in brain, HPA axis, and metabolic functions (Houshyar et al., 2004) . Stressors trigger endocrine and behavioral adaptive responses that are aimed at reinstating homeostasis. The brain extrahypothalamic CRF/CRF 1 receptor pathway and the HPA axis are major components of the stress-responsive system (de Kloet et al., 2005) . CRF 1 À/À mice display consistent alterations in stress-related affective-like behaviors, a pronounced atrophy of the corticosterone-producing zona fasciculata of the adrenal gland cortex and deficient ACTH and corticosterone responses to stressors (Contarino et al., 1999; Contarino and Papaleo, 2005; Smith et al., 1998; Timpl et al., 1998) . Here, we provide initial evidence that genetic disruption of the HPA axis and brain extrahypothalamic CRF/CRF 1 receptor circuitry increased both the severity and the duration of somatic signs of opiate withdrawal. These findings clearly indicate that failure to adequately activate stress-responsive CRF/CRF 1 receptor circuitry may lead to exaggerated somatic reactions to opiate withdrawal. The present gene expression studies add novel evidence in favor of a disrupted stress-responsive system in CRF 1 À/À mice. Here, we examined CRF and dynorphin Neuron expression in the PVN and the striatum, brain regions implicated in behavioral, endocrine, and autonomic responses to stress (Koob and Heinrichs, 1999; Reyes et al., 2005) . Activation of PVN CRF circuitry is pivotal for coordinating HPA axis and behavioral-adaptive responses to severe stressors. Accordingly, here we show that both wild-type and CRF 1 +/À mice responded to the stress of opiate withdrawal with an increase in PVN CRF expression. In net contrast, in CRF 1 À/À mice opiate withdrawal induced an aberrant decrease in PVN CRF activity, indicating profound impairments in key substrates underlying adaptive responses to drug withdrawal-related stressful conditions. Circulating glucocorticoid hormones regulate basal and stress-related activity of PVN CRF circuitry (Tanimura and Watts, 1998) . We hypothesized that the glucocorticoid deficiency associated with the genetic disruption of the CRF/CRF 1 receptor pathway contributed to deregulate both basal and opiate withdrawal-related PVN CRF expression, thus exaggerating the somatic reactions to opiate withdrawal. To address this question, CRF 1 À/À mice were given free access to corticosterone in the home-cage drinking water prior to and throughout intermittent morphine treatment. We found that intake of nonstressful amounts of corticosterone effectively reduced the exaggerated somatic reactions of CRF 1 À/À mice to opiate withdrawal. In particular, corticosterone intake clearly decreased the expression of paw tremors and wet dog shakes in opiate-withdrawn CRF 1 À/À mice, completely eliminating the difference with the wild-type mice. Corticosterone also markedly downregulated PVN CRF expression in drug-naive CRF 1 À/À mice, as compared to corticosterone-untreated drug-naive CRF 1 À/À mice.
Most interestingly, unlike the aberrant decrease in PVN CRF expression observed in corticosterone-untreated opiate-withdrawn CRF 1 À/À mice, intake of nonstressful amounts of corticosterone fully restored ''wild-type-like'' patterns of PVN CRF activation in opiate-withdrawn CRF 1 À/À mice. Most likely, the ''beneficial'' behavioral effects of exogenous corticosterone observed here were due to enduring changes in the HPA system, which were taking place throughout the entire period of free access to the glucocorticoid hormone in the drinking water. Notably, changes in the activity of the type 2 corticosteroid receptor, glucocorticoid receptor (GR), may have underlain the corticosterone effects reported here. We have preliminary data indicating increased GR nuclear translocation in the hypothalamus and hippocampus of CRF 1 À/À mice, which is normalized by the same corticosterone treatment used here (P.K., A.C., F.P., and P. Piazza, unpublished data). In support of a role for the GR in the stress response, studies have shown increased behavioral reactivity to stressors in mice with PVN and hippocampal GR overexpression (Wei et al., 2004) . Activation of PVN GR by glucocorticoid hormones is thought to downregulate the expression of CRF in this brain region (Sawchenko, 1987 Our studies also revealed elevated PVN dynorphin expression in drug-naive corticosterone-untreated CRF 1 À/À mice. Upregulated PVN dynorphin activity might indicate a chronic ''stress-like'' state. Stressors increase dynorphin immunoreactivity in limbic brain regions (Shirayama et al., 2004) and in the hypothalamus (Nabeshima et al., 1992) , and pharmacological as well as genetic disruption of dynorphin activity attenuate the behavioral effects of stress exposure (McLaughlin et al., 2003; Shirayama et al., 2004) . We also found that, despite the elevated ''basal'' dynorphin mRNA levels, opiate withdrawal further increased PVN dynorphin expression in corticosteroneuntreated CRF 1 À/À mice. Corticosterone intake decreased both basal and opiate withdrawal-related PVN dynorphin expression in CRF 1 À/À mice. In particular, at both coronal slices examined in the present study, opiate-withdrawn corticosterone-treated CRF 1 À/À mice showed lower PVN mRNA dynorphin levels than opiatewithdrawn corticosterone-untreated CRF 1 À/À mice. PVN dynorphin neurons project to autonomic nervous system centers that are activated during opiate withdrawal, such as the nucleus of the tractus solitarius, the parabrachial nucleus, and the spinal cord (Fallon and Ciofi, 1990; Stornetta et al., 1993) . Thus, we cannot exclude a role for the corticosterone-linked PVN dynorphin expression in the decreased somatic opiate withdrawal displayed by corticosterone-treated CRF 1 À/À mice. However, despite the similar somatic opiate withdrawal profiles, the level of PVN dynorphin expression found in corticosteronetreated CRF 1 À/À mice differed from that observed in opiate-withdrawn wild-type mice. Thus, further studies might be needed to better understand the implication of the glucocorticoid-dependent PVN dynorphin activity in the exacerbated somatic reactions of CRF 1 À/À mice to opiate withdrawal. The present molecular biology studies also showed that drug-naive corticosterone-untreated CRF 1 À/À mice displayed a marked decrease in striatal dynorphin gene expression, as compared to wild-type mice. The decreased dynorphin expression found in the striatum of CRF 1 À/À mice may have function to exacerbate the somatic consequences of opiate exposure and withdrawal. Accordingly, mice overexpressing DFosB in dynorphin neurons of the striatum and the nucleus accumbens displayed decreased dynorphin mRNA levels in the striatum as well as increased somatic signs of opiate withdrawal (McClung et al., 2004; Zachariou et al., 2006) . Accordingly, studies have shown that withdrawal from an intermittent morphine treatment similar to that used here increased DFosB immunoreactivity in the striatum (Muller and Unterwald, 2005) . Thus, since intake of corticosterone reduced the severity of somatic opiate withdrawal, we examined striatal dynorphin expression in drug-naive or opiate-withdrawn wild-type, corticosterone-untreated or -treated CRF 1 À/À mice. Treatment with corticosterone increased the striatal expression of dynorphin in drug-naive CRF 1 À/À mice. The latter results agree with prior studies showing decreased striatal dynorphin expression in adrenalectomized rats, which is upregulated by exogenous corticosterone (Lucas et al., 1998) . Moreover, in net contrast with the aberrant increase observed in corticosteroneuntreated CRF 1 À/À mice, opiate withdrawal decreased the expression of striatal dynorphin in corticosteronetreated CRF 1 À/À mice, a pattern similar to that observed in wild-type mice. Overall, our results suggest that upregulated dynorphin expression induced by exogenous corticosterone may have ''protected'' the CRF 1 À/À mice from the negative consequences of opiate exposure and withdrawal. Together with recent studies (Zachariou et al., 2006) , the present findings add further support to a previously unsuspected role for dysregulated striatal dynorphin activity in somatic components of the opiate withdrawal syndrome. The use of antalarmin allowed us to examine the HPA axis-independent role for the CRF/CRF 1 receptor pathway in opiate withdrawal. Antalarmin is a highly lipophilic CRF 1 receptor-preferring antagonist that, following peripheral administration, readily crosses the blood-brain barrier and does not affect HPA axis responses to stressors. Both acute and chronic antalarmin failed to blunt ACTH and corticosterone responses to either an immobilization or a swim stress (Jutkiewicz et al., 2005; Wong et al., 1999) . Accordingly, in the present study antalarmin did not reduce HPA axis responses to the stress of opiate withdrawal. In contrast, antalarmin reliably increased the somatic expression of opiate withdrawal in both wild-type and CRF 1 +/À mice. Thus, in spite of a preserved stresslike HPA axis activity, disruption of the extrahypothalamic brain CRF/CRF 1 receptor pathway exacerbated the somatic expression of opiate withdrawal. These results unravel an inhibitory role for central CRF/CRF 1 receptor circuitry upon somatic features of opiate withdrawal, which may be independent of the HPA axis. Our findings contrast with prior studies showing reduction of somatic opiate withdrawal by other CRF 1 receptor-preferring antagonists (Iredale et al., 2000; Lu et al., 2000) . However, the latter studies employed opioid-receptor antagonistprecipitated opiate withdrawal procedures whereas herein we used a more clinically relevant spontaneous opiate withdrawal paradigm. Major behavioral and molecular differences between spontaneous and opioid-receptor antagonist-precipitated opiate withdrawal procedures (Fukunaga and Kishioka, 2000; Houshyar et al., 2004; Linseman, 1977) make it difficult to compare the present with prior studies.
We have recently reported that either CRF 1 +/À or CRF 1 À/À mice lack the affective-like signs of opiate withdrawal (Contarino and Papaleo, 2005) . Here, we clearly show that CRF 1 À/À mice display increased somatic reactions to opiate withdrawal, which are abolished by treatment with corticosterone. Also, in response to opiate withdrawal, neither CRF 1 +/À nor CRF 1 À/À mice displayed increased dynorphin activity in the shell portion of the nucleus accumbens (Contarino and Papaleo, 2005) , a brain region underlying negatively valenced affective states (Nestler, 2001) . Moreover, here we show that opiate-withdrawn CRF 1 À/À mice displayed aberrant CRF and dynorphin expression in the PVN and the striatum, which were reversed by intake of nonstressful amounts of corticosterone. Thus, the increased somatic opiate withdrawal displayed by CRF 1 À/À mice largely depended on the impaired HPA axis associated with the genetic inactivation of the CRF/CRF 1 receptor pathway. In contrast, the HPA axis may be less involved in the affective components of the opiate withdrawal syndrome since neither CRF 1 +/À nor CRF 1 À/À mice, which greatly differ in both basal and stress-related HPA axis activity (Contarino and Papaleo, 2005; Timpl et al., 1998) , showed the negative affectivelike states of opiate withdrawal (Contarino and Papaleo, 2005) . Human as well as rodent studies indicate that somatic and affective components of the opiate withdrawal syndrome are dissociable at a number of levels of analysis (Mucha, 1987; Schulteis and Koob, 1996) . Our findings of a clear-cut dissociation of affective-like and somatic signs of opiate withdrawal in CRF 1 receptor-deficient mice provide novel and robust evidence in support of the latter notion. The opposite changes in somatic and affective-like signs of opiate withdrawal found in CRF 1 receptor-deficient mice point to this genetically engineered mouse model as a unique tool to determine the relative contribution of opiate withdrawal-induced somatic malaise and negative affective states to opiate dependence.
In conclusion, here we show that disruption of major components of the stress-responsive system exacerbates the somatic expression of opiate withdrawal and induces brain and endocrine changes suggestive of increased somatic vulnerability to the stress of opiate withdrawal. The vast majority of the studies carried out to date indicate that acute withdrawal from essentially all drugs of abuse is associated with increased HPA axis and brain extrahypothalamic CRF activity, which are thought to underlie the negative consequences of drug withdrawal (Koob and Le Moal, 2001; Kreek and Koob, 1998) . The findings of the present study demonstrate that, like hyperactive stress systems, severe deficiencies in major components of the stress-responsive system may worsen the somatic reactions to drug withdrawal.
EXPERIMENTAL PROCEDURES
Subjects
Group-housed, littermate, female mice that were wild-type, CRF 1 -receptor heterozygous (CRF 1 +/À ) or homozygous (CRF 1 À/À ) were used throughout (Smith et al., 1998 Pharmacological Antagonism of the CRF/CRF 1 Receptor Pathway Wild-type and CRF 1 +/À mice were treated with morphine as described above. Eight hours after the last drug injection, the mice were tested for the occurrence of somatic opiate withdrawal signs. Forty-five minutes prior to the test, within each genotype mice were treated with the appropriate vehicle or antalarmin (20 mg/kg, i.p.).
CRF and Dynorphin In Situ Hybridization Histochemistry
At the end of the 30 min somatic opiate withdrawal test, the mice were taken into another room, their brains rapidly removed, frozen in isopentane (À40 C), and then stored at À80 C. Brains were cut in coronal sections (12 mm) using a cryostat and thaw mounted onto gelatincovered slides to be processed for in situ hybridization. The in situ hybridization procedure was performed with oligonucleotide probes designed to recognize the dynorphin (Jaber et al., 1995) France) using terminal deoxynucleotide transferase (Promega, Madison, WI). The specific activity of the oligonucleotide probes was 45 3 10 7 cpm/mg and 65 3 10 7 cpm/mg for dynorphin and CRF, respectively. After labeling, the probes were precipitated in absolute ethanol and 5 M sodium chloride, dried, and resuspended at the concentration of 4.25 pg/ml in the hybridization buffer (50% deionized formamide, 20% dextran sulfate, 20% 203 SSC, sodium chloride-sodium citrate, 500 mg/ml denatured salmon sperm DNA, 1% Denhardt, 5% sarcosyl, 240 mg/ml tRNA, 2.4 mg/ml NaH 2 PO 4 ). The sections were fixed with 4% paraformaldehyde in phosphate buffer 0.1 M (pH 7.2) for 5 min at room temperature, rinsed twice for 30 min with 43 SSC (2% Denhardt), acetylated into 43 SSC (0.25% acetic anhydride, 1.33% triethanolamine [pH 8]) for 10 min at room temperature and then dehydrated in graded alcohol. The slides were then incubated horizontally overnight at 40 C with the hybridization solution containing the labeled probe (40 ml/slide). At the end of the incubation, slides were washed in decreasing concentrations of SSC and dehydrated in ethanol. Sections were exposed at room temperature to Biomax-MR film (Kodak, Polylabo, Strasbourg, France) over 15-20 days. The Biomax-MR films were quantified using a GS-800 scanner (in transmission mode) and the associated Quantity One software (Bio-Rad Laboratories, Hercules, CA (Paxinos and Franklin, 2001 ).
Treatment with Corticosterone and Plasma Corticosterone Assay
Wild-type and CRF 1 À/À mice were injected with vehicle or morphine and tested for somatic opiate withdrawal 8 hr after the last injection, as described above. Starting 5 days prior to the beginning of and throughout intermittent vehicle or morphine administration, 15 out of 36 CRF 1 À/À mice were treated with corticosterone. Briefly, corticosterone (Sigma-Aldrich, St. Louis, MO) was dissolved in 95% ethanol and then added to the home-cage drinking water (5 mg/ml; final concentration of ethanol was 0.2%). Wild-type and corticosterone-untreated CRF 1 À/À mice had the same ethanol concentration in the drinking water. On the day prior to the beginning of vehicle or morphine administration, two tail blood samples were collected from each mouse at 9 a.m. and 9 p.m. Immediately after the 30 min opiate withdrawal test, blood samples were collected from the trunk and brains rapidly removed for later in situ hybridization studies. Plasma samples were stored at À20 C until corticosterone assay. Plasma corticosterone levels were quantified by radioimmunoassay (RIA) using a specific corticosterone antibody (ICN Pharmaceuticals). The intra-and interassay coefficients of variation were approximately 3.5% and 8%, respectively.
Drugs
Morphine HCl (SALARS, Como, Italy; 20-100 mg/kg, i.p.) was dissolved in physiological saline. Antalarmin (20 mg/kg, i.p.) was suspended in carboxymethylcellulose (0.5%) and dissolved in physiological saline (pH of diluent was 4.1-4.5). The volume of the injections was 10 ml/kg throughout. Within each experiment, control mice were injected with the appropriate vehicle.
Statistical Analysis
The two-way analysis of variance (ANOVA) with genotype (wild-type, CRF 1 +/À or CRF 1 À/À mice) and treatment (control or opiate-withdrawn)
as independent variables was used to examine somatic opiate withdrawal signs observed 8 hr after the last vehicle or morphine injection, and CRF and dynorphin mRNA levels of the PVN. The three-way ANOVA with genotype and treatment as between subjects factors and time as a within-subject repeated measure was used to analyze percentage of BW loss during intermittent morphine treatment, and GOW scores recorded 32, 56, 80, 104, 128 , and 152 hr after the last vehicle or morphine injection. The two-way ANOVA with genotype (wild-type or CRF 1 +/À mice) and treatment (vehicle or antalarmin) as
independent variables was used to analyze somatic opiate withdrawal signs of the antalarmin study. The two-way ANOVA with group (wildtype, corticosterone-untreated, or -treated CRF 1 À/À mice) and treatment (control or opiate-withdrawn) as independent variables was used to examine somatic opiate withdrawal signs as well as PVN and the striatal CRF and dynorphin mRNA levels of the corticosterone study. The one-way ANOVA was used to examine baseline and opiate withdrawal-related plasma corticosterone levels of wild-type, corticosterone-untreated, or -treated CRF 1 À/À mice. The Student-NewmanKeuls post-hoc test was used for individual group comparisons. The accepted value for significance was p < 0.05.
Supplemental Data
The Supplemental Data for this article can be found online at http:// www.neuron.org/cgi/content/full/53/4/577/DC1/.
